⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27813692 | 0.85 | — | — | |
| SCHEMBL2711926 | 0.73 | — | — | |
| SCHEMBL3882907 | 0.73 | — | — | |
| SCHEMBL33897 | 0.69 | — | — | |
| Lithium SCHEMBL29542569 | 0.66 | — | — | |
| Hydrochloric Acid SCHEMBL11714389 | 0.66 | — | — | |
| SCHEMBL121236 | 0.59 | — | — | |
| SCHEMBL3833318 | 0.59 | — | — | |
| Aziridine SCHEMBL6424974 | 0.59 | — | — | |
| Lithium SCHEMBL31187740 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025002179-A1 | HETEROTRICYCLIC N-[1-(2-BENZOFURANYL)-METHYL]-UREA DERIVATIVES AS PI3K ALPHA INHIBITORS FOR THE TREATMENT OF CANCER | LAEKNA PHARMACEUTICAL NINGBO CO., LTD. (CN) | 2025-01-02 | — | — | WO | claimed |
| CN-115776907-A | MTORC1 modulators and uses thereof | 艾奥维安制药公司 | 2023-03-10 | — | — | CN | claimed |
| EP-4126229-A1 | MTORC1 MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| US-11478438-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2022-10-25 | — | — | US | claimed |
| WO-2021195599-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2021-09-30 | — | — | WO | claimed |
| EP-3883925-A1 | CYCLIC UREAS | Sironax Ltd (KY) | 2021-09-29 | — | — | EP | claimed |
| US-20210292305-A1 | Cyclic Ureas | SIRONAX LTD (KY) | 2021-09-23 | — | — | US | claimed |
| US-20200182617-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-06-11 | — | — | US | claimed |
| US-10555920-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-02-11 | — | — | US | claimed |
| US-20190038578-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2019-02-07 | — | — | US | claimed |
| JP-4676960-B2 | — | — | 2011-04-27 | — | — | JP | claimed |
| WO-2011011722-A1 | SUBSTITUTED BENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS | VANDERBILT UNIVERSITY (US) | 2011-01-27 | — | — | WO | claimed |
| US-20090275523-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2009-11-05 | — | — | US | claimed |
| US-7196103-B2 | Indole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-27 | — | — | US | claimed |
| JP-2006528940-A | — | — | 2006-12-28 | — | — | JP | claimed |
| EP-1633746-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-15 | — | — | EP | claimed |
| US-20050033049-A1 | Indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-10 | — | — | US | claimed |
| WO-2004101554-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | claimed |
| EP-1479677-A1 | New indole derivatives as factor xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | claimed |
| EP-0312794-B1 | THIAZETIDINE DERIVATIVES | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1993-05-19 | — | — | EP | claimed |